Compare LQDT & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LQDT | TBPH |
|---|---|---|
| Founded | 1999 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 985.8M | 824.9M |
| IPO Year | 2005 | 2013 |
| Metric | LQDT | TBPH |
|---|---|---|
| Price | $35.31 | $16.79 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $40.00 | $18.40 |
| AVG Volume (30 Days) | 134.2K | ★ 414.8K |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 38.10 | ★ 279.13 |
| EPS | 0.23 | ★ 2.06 |
| Revenue | ★ $476,669,000.00 | $15,386,000.00 |
| Revenue This Year | N/A | $8.46 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $151.17 | ★ $7.97 |
| Revenue Growth | ★ 31.20 | N/A |
| 52 Week Low | $21.67 | $8.33 |
| 52 Week High | $35.16 | $21.03 |
| Indicator | LQDT | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 77.21 | 57.45 |
| Support Level | $30.51 | $13.41 |
| Resistance Level | N/A | $17.24 |
| Average True Range (ATR) | 0.84 | 0.41 |
| MACD | 0.23 | 0.02 |
| Stochastic Oscillator | 91.45 | 59.28 |
Liquidity Services Inc is an online auction marketplace. It manages and sells inventory and equipment for business and government clients by operating a network of e-commerce marketplaces that enable buyers and sellers to transact in an efficient, automated environment offering across different product categories. The company has four reportable segments: GovDeals, Retail Supply Chain Group (RSCG), and Machinio & Software Solutions. It generates majority of its revenue from Retail Supply Chain Group (RSCG) segment which consists of marketplaces that enable corporations located in the United States and Canada to sell excess, returned, and overstocked consumer goods. Geographically, a substantial portion the company's revenue is generated from its business in United States.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.